GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Loans Receivable

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Loans Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Loans Receivable?

60 Degrees Pharmaceuticals's Loans Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.


60 Degrees Pharmaceuticals Loans Receivable Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Loans Receivable Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Loans Receivable
- - - -

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

60 Degrees Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


60 Degrees Pharmaceuticals Loans Receivable Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.